Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 234

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Repurposing atovaquone: Targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells

Open access
Fiorillo, Marco, Lamb, Rebecca, Tanowitz, Herbert B., Mutti, Luciano, Krstic-Demonacos, Marija, Cappello, Anna Rita, Martinez-Outschoorn, Ubaldo E., Sotgia, Federica, Lisanti, Michael P. · 2016 · Oncotarget

Abstract

// Marco Fiorillo 1,2,3 , Rebecca Lamb 1 , Herbert B. Tanowitz 4 , Luciano Mutti 5 , Marija Krstic-Demonacos 5 , Anna Rita Cappello 3 , Ubaldo E. Martinez-Outschoorn 6 , Federica Sotgia 1,2 and Michael P. Lisanti 1,2 1 The Breast Cancer Now Research Unit, Institute of Cancer Sciences, Cancer Research UK Manchester Institute, University of Manchester, Manchester, UK 2 The Manchester Centre for Cellular Metabolism (MCCM), Institute of Cancer Sciences, Cancer Research UK Manchester Institute, University of Manchester, Manchester, UK 3 The Department of Pharmacy, Health and Nutritional Sciences, The University of Calabria, Cosenza, Italy 4 Department of Medicine and Pathology, Albert Einstein College of Medicine, Bronx, NY, USA 5 School of Environment and Life Sciences, University of Salford, Salford, UK 6 The Sidney Kimmel Cancer Center, Philadelphia, PA, USA Correspondence to: Michael P. Lisanti, email: // Federica Sotgia, email: // Keywords : atovaquone, tumor-initiating cells (TICs), mitochondria, OXPHOS, cancer stem-like cells (CSCs) Received : January 08, 2016 Accepted : January 27, 2016 Published : April 30, 2016 Abstract Atovaquone is an FDA-approved anti-malarial drug, which first became clinically available in the year 2000. Currently, its main usage is for the treatment of pneumocystis pneumonia (PCP) and/or toxoplasmosis in immune-compromised patients. Atovaquone is a hydroxy-1,4-naphthoquinone analogue of ubiquinone, also known as Co-enzyme Q10 (CoQ10). It is a well-tolerated drug that does not cause myelo-suppression. Mechanistically, it is thought to act as a potent and selective OXPHOS inhibitor, by targeting the CoQ10-dependence of mitochondrial complex III. Here, we show for the first time that atovaquone also has anti-cancer activity, directed against Cancer Stem-like Cells (CSCs). More specifically, we demonstrate that atovaquone treatment of MCF7 breast cancer cells inhibits oxygen-consumption and metabolically induces aerobic glycolysis (the Warburg effect), as well as oxidative stress. Remarkably, atovaquone potently inhibits the propagation of MCF7-derived CSCs, with an IC-50 of 1 μM, as measured using the mammosphere assay. Atovaquone also maintains this selectivity and potency in mixed populations of CSCs and non-CSCs. Importantly, these results indicate that glycolysis itself is not sufficient to maintain the proliferation of CSCs, which is instead strictly dependent on mitochondrial function. In addition to targeting the proliferation of CSCs, atovaquone also induces apoptosis in both CD44+/CD24low/- CSC and ALDH+ CSC populations, during exposure to anchorage-independent conditions for 12 hours. However, it has no effect on oxygen consumption in normal human fibroblasts and, in this cellular context, behaves as an anti-inflammatory, consistent with the fact that it is well-tolerated in patients treated for infections. Future studies in xenograft models and human clinical trials may be warranted, as the IC-50 of atovaquone’s action on CSCs (1 μM) is >50 times less than its average serum concentration in humans.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.9122

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 234

Metadata

Authors
Fiorillo, M., Lamb, R., Tanowitz, H. B., Mutti, L., Krstic-Demonacos, M., Cappello, A. R., Martinez-Outschoorn, U. E., Sotgia, F., & Lisanti, M. P.
Venue
Oncotarget
Published
2016-04-30
Volume
7
Issue
23
Pages
34084-34099
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2304994032
Cited by
234
References
3
FWCI
8.25
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.